Exclusive Summary

• Adopting the Technology Transfer (TT) model for biosimilars empowers overseas pharmaceutical companies to break through monoclonal antibody (mAb) development barriers, perfectly aligning with tendering preference policies for 'Local Manufacturing' in emerging markets.
• Targeting the global $100+ billion autoimmune disease market by offering a validated, high-barrier replacement solution for the foundational blockbuster Humira (peak historical sales >$21.2 billion).
• Delivering a comprehensive technical package containing validated cell lines, manufacturing processes, and QA/QC standards to significantly reduce early-stage trial-and-error costs and accelerate regional commercial timelines.
• Localized production structurally avoids expensive cross-border cold chain logistics and import tariffs, creating a disruptive pricing advantage to undercut the reference product by 50%-80% or more.